Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 8/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 3/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 8/20 | 0.71 |
| ▸ | HIF1A | Q16665 | 7/20 | 0.71 |
| ▸ | AR | P10275 | 7/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.71 |
| ▸ | LMNA | P02545 | 3/20 | 0.71 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.71 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diflucortolone SCHEMBL3796 | 1.00 | PGR (1.00) | PGRNR1I2HTR2BNR3C1HIF1A | |
| Diflucortolone SCHEMBL11338795 | 1.00 | PGR (1.00) | PGRNR1I2HTR2BNR3C1HIF1A | |
| Diflucortolone SCHEMBL5484149 | 1.00 | PGR (1.00) | PGRNR1I2HTR2BNR3C1HIF1A | |
| Diflucortolone SCHEMBL3794 | 1.00 | PGR (1.00) | PGRNR1I2HTR2BNR3C1HIF1A | |
| Diflucortolone SCHEMBL11856229 | 1.00 | PGR (1.00) | PGRNR1I2HTR2BNR3C1HIF1A | |
| Diflucortolone SCHEMBL3795 | 1.00 | PGR (1.00) | PGRNR1I2HTR2BNR3C1HIF1A | |
| Diflucortolone SCHEMBL11855200 | 1.00 | PGR (1.00) | PGRNR1I2HTR2BNR3C1HIF1A | |
| Diflucortolone SCHEMBL10052991 | 1.00 | PGR (1.00) | PGRNR1I2HTR2BNR3C1HIF1A | |
| Diflucortolone SCHEMBL22040571 | 1.00 | PGR (1.00) | PGRNR1I2HTR2BNR3C1HIF1A | |
| Diflucortolone SCHEMBL22039899 | 1.00 | PGR (1.00) | PGRNR1I2HTR2BNR3C1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021360-A1 | Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase | EPIGENESIS PHARMACEUTICALS, LLC | 2007-01-25 | — | — | US | claimed |
| US-4296109-A | ANTISHOCK, ANTIINFLAMMATORY | SCHERING, AKTIENGESELLSCHAFT (DE) | 1981-10-20 | — | — | US | disclosed |
| US-3984544-A | Retinoic acid esters of steroids of the pregnane series, their use in the treatment of acne and pharmaceutical formulations useful therefor | SCHERING CORPORATION (US) | 1976-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021360-A1 | Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase | RECQL, GSS, DDX17 | PGR 965/4885NR1I2 1178/4885HTR2B 3075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.